OpenNashPodcasts

Person

Bapu Jena

7 episodes · 74 quoted claims

Sickle cell disease occurs in about 1 out of every 365 Black or African American births in the United States, according to host Bapu Jena.

“In fact, sickle cell disease occurs in around 1 out of every 365 Black or African American births.”

Freakonomics, M.D. · 0:01:45

Nigeria has one of the world's largest sickle cell disease populations, at around 4 to 6 million people, according to the host.

“But he's originally from Nigeria, which has one of the largest sickle cell disease populations in the world. at around 4 to 6 million people.”

Freakonomics, M.D. · 0:01:45

Sickle cell disease is caused by a single mutation in a single gene, which makes red blood cells rigid and sickle-shaped.

“It's caused by a single mutation in a single gene. People with sickle cell disease produce red blood cells that are rigid and sickle-shaped.”

Freakonomics, M.D. · 0:02:19

In January 2020 Jimmy Olaher, his wife and their newborn moved part-time to Nashville, where his CRISPR sickle cell trial took place.

“In January 2020, Jimmy, his wife, and their newborn moved part-time to Nashville, where the trial was taking place”

Freakonomics, M.D. · 0:04:28

Jimmy Olaher received his CRISPR infusion in September 2021, about 18 months after starting the preparation process.

“Finally, 18 months later, in September 2021, it was time.”

Freakonomics, M.D. · 0:04:28

CRISPR consists of two molecules: an enzyme that acts as DNA scissors and a piece of genetic material that tells the enzyme where to cut.

“it consists of just two molecules, an enzyme that acts as a pair of DNA scissors, and a special piece of genetic material that tells the enzyme where in the DNA to cut.”

Freakonomics, M.D. · 0:05:25

Gene therapies that existed before CRISPR relied on modified viruses to deliver new genetic material into a patient's cells.

“There were gene therapies before CRISPR, but they relied on modified viruses to deliver new genetic material into a patient's cells.”

Freakonomics, M.D. · 0:06:00

The CRISPR treatment that cured Jimmy Olaher's sickle cell disease is the first CRISPR-based therapeutic up for approval by the U.S. FDA.

“The treatment that cured Jimmy's sickle cell disease is now the first CRISPR-based therapeutic up for approval by the FDA, meaning it could hit the market as early as this year.”

Freakonomics, M.D. · 0:06:00

A hemophilia gene therapy cure became the world's most expensive drug when it launched at $3.5 million per treatment.

“Last year, a gene therapy cure for the blood clotting disorder hemophilia broke the record for the most expensive drug in the world when it hit the market at $3.5 million per treatment.”

Freakonomics, M.D. · 0:06:35

Andrew Lowe published a paper in 2016 proposing a mortgage-like payment model to finance expensive cures.

“Economist Andrew Lowe published a paper in 2016 proposing we use a similar payment model to finance expensive cures for chronic diseases.”

Freakonomics, M.D. · 0:16:32

Andrew Lowe co-founded a company that would act as a payment platform for a drug subscription model.

“I should note that Andrew Lowe co-founded a company that would act as a payment platform for such a subscription model.”

Freakonomics, M.D. · 0:17:40

Gilead's hepatitis C drug Sovaldi was approved by the FDA and came to market in December 2013.

“The medication was approved by the FDA and came to market in December 2013.”

Freakonomics, M.D. · 0:18:03

The three most expensive drugs in the world are all treatments for rare genetic diseases approved within the past few years, according to the host.

“Today, the three most expensive drugs in the world are all treatments for rare genetic diseases, all approved within the past few years.”

Freakonomics, M.D. · 0:21:00

Over 200 million statin prescriptions are filled in the United States each year, according to the host.

“Over 200 million statin prescriptions are filled in the U.S. each year.”

Freakonomics, M.D. · 0:25:07

Scientists who developed statins in the mid-1980s were aiming to treat the genetic disease familial hypercholesterolemia.

“The scientists who developed statins in the mid-1980s were hoping to cure a genetic disease called familial hypercholesterolemia”

Freakonomics, M.D. · 0:25:38

The host says nearly 30 million Americans have no health insurance and would be left out of the subscription model.

“And what about the nearly 30 million Americans who don't have any health insurance?”

Freakonomics, M.D. · 0:24:15

Bapu Jena and a colleague named Athena later used the 1987 NFL Players Association strike as a natural experiment to study whether playing pro football affects health.

“In 1987, the NFL Players Association held a strike. 30 years later, my friend Athena and I did a study that used that strike as a natural experiment”

Freakonomics, M.D. · 0:30:04

The National Institutes of Health invests more than $40 billion in biomedical research each year.

“The National Institutes of Health invest more than $40 billion in biomedical research each year.”

Freakonomics, M.D. · 0:02:08

The US private sector spends more than twice the NIH's research budget on biomedical research.

“And the private sector in the U.S. spends more than twice that.”

Freakonomics, M.D. · 0:02:42

The US government defines a rare disease as one affecting fewer than 200,000 people in the country.

“The U.S. government defines rare diseases as those that affect fewer than 200 ,000 people in the country.”

Freakonomics, M.D. · 0:09:08

More than 30 million people in the United States have been diagnosed with a rare disease, around 10% of the population.

“Taken altogether, more than 30 million people in the United States have been diagnosed with a rare disease.”

Freakonomics, M.D. · 0:09:08

The first complete human genome sequence took about a decade and $3 billion to obtain.

“The first complete sequence of the human genome was obtained two decades ago. It took about a decade and $3 billion.”

Freakonomics, M.D. · 0:11:46

Fyodor Urnov says that as of January 2023 a person's complete genetic sequence could be obtained within 24 hours of a swab.

“And 24 hours later, you can get a link to your complete genetic sequence.”

Freakonomics, M.D. · 0:12:11

Fyodor Urnov says human DNA carries about 20,000 genes.

“In you and I, it carries 20 ,000 such genetic instructions, which we call genes.”

Freakonomics, M.D. · 0:17:35

A mutation around 5,000 years ago allowed humans to digest lactose, according to Fyodor Urnov.

“like a mutation that occurred around 5 ,000 years ago that allowed humans to digest lactose for the first time.”

Freakonomics, M.D. · 0:18:09

About 100,000 Americans have sickle cell disease, so it is classified as a rare disease.

“Around 100 ,000 Americans suffer from it, so we classify it as a rare disease,”

Freakonomics, M.D. · 0:18:56

Sickle cell disease results from a single changed letter among 6 billion in the genome.

“All of these bad outcomes are the result of just one letter out of 6 billion in the genome being flipped.”

Freakonomics, M.D. · 0:19:34

Fyodor Urnov says Americans with sickle cell disease have a lifespan around the mid-40s even with the best care.

“even with the best health care, our fellow Americans with sickle cell disease, their lifespan is around the mid-40s.”

Freakonomics, M.D. · 0:20:10

Until CRISPR therapy, bone marrow transplant was the only cure for sickle cell disease.

“Until now, the only way to cure sickle cell disease was with a bone marrow transplant.”

Freakonomics, M.D. · 0:20:10

Jennifer Doudna and Emmanuel Charpentier won the 2020 Nobel Prize in Chemistry for their CRISPR discovery.

“That discovery was made by the biochemist Jennifer Doudna, who, together with Emmanuel Charpentier, won the 2020 Nobel Prize in Chemistry.”

Freakonomics, M.D. · 0:21:54

CRISPR is a bacterial defense mechanism consisting of a DNA-cutting enzyme and a guide molecule.

“It's a microbial defense mechanism. It consists of just two molecules, an enzyme that acts as a pair of DNA scissors”

Freakonomics, M.D. · 0:21:54

A CRISPR-based sickle cell therapy was the first CRISPR therapeutic up for FDA approval at the time of recording.

“Geneticists made use of that function to develop a cure for sickle cell disease, which is currently the first CRISPR-based therapeutic up for approval by the FDA.”

Freakonomics, M.D. · 0:24:15

CRISPR has been used to treat genetic diseases of the blood, liver, eye and immune system.

“So far, CRISPR has been used to treat genetic diseases of the bloodstream, liver, eye, and immune system”

Freakonomics, M.D. · 0:24:50

Huntington's disease, which killed Woody Guthrie, is caused by a toxic gene and is usually diagnosed after brain damage has occurred.

“A really profound and poignant example is the disease that killed woody guthrie which is huntington's disease”

Freakonomics, M.D. · 0:29:30

Albert Bourla became Pfizer's chief operating officer in 2018 and its CEO in 2019.

“In 2018, he became chief operating officer and the following year, CEO.”

Freakonomics, M.D. · 0:07:28

Host Bapu Jena says vaccines typically take 5 to 10 years to develop and manufacture, and often longer.

“It typically takes 5 to 10 years to develop and manufacture a vaccine, and often it takes even longer.”

Freakonomics, M.D. · 0:18:34

Bapu Jena says Pfizer and other drug makers brought COVID vaccines to market in less than a year.

“Pfizer and the other pharmaceutical makers brought their COVID vaccines to market in less than a year.”

Freakonomics, M.D. · 0:19:12

Bapu Jena says that in the initial approval study, Paxlovid taken early cut the risk of serious illness or death from COVID by around 90% in high-risk unvaccinated people.

“When they took Paxlovid early in their infection, it reduced the risk of serious illness or death from COVID by around 90%.”

Freakonomics, M.D. · 0:27:46

Bapu Jena says only around one-third of Americans had received a booster dose at the time of the interview.

“It's been a struggle to get some people to take their first, second, and now third or fourth COVID vaccines. Only around one-third of Americans are boosted.”

Freakonomics, M.D. · 0:27:14

Bapu Jena says Bourla told him Pfizer expected to submit data on a three-dose series for children under five, with a third dose appearing to add substantial protection.

“Pfizer expects to submit its data this month on the efficacy of a three-dose series for these kids, and that adding a third dose seemed to provide substantially more protection against COVID compared to just two doses.”

Freakonomics, M.D. · 0:27:14